Form 4 for ACAD ACADIA PHARMACEUTICALS INC
Accepted 2026-08-07 18:00:09 ET · period of report 2026-08-05 · accession 0001899977-26-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-08-07 18:00 | 2026-08-05+ | ACAD | Schneyer Mark C. | EVP, CFO | M - OptEx | $17.84 | +20.1K | 82.1K | +32% | +$359.3K |
| DMT | 2026-08-07 18:00 | 2026-08-05+ | ACAD | Schneyer Mark C. | EVP, CFO | S - Sale+OE | $29.16 | -20.1K | 67.8K | -23% | -$587.2K |
| DMT | 2026-08-07 18:00 | 2026-08-05+ | ACAD | Schneyer Mark C. | EVP, CFO | M - OptEx | $0.00 | -20.1K | 60.4K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-05 | M | A | 5,849 | $17.84 | 73,677 | D | — | — | (F1) Includes 1,683 shares of the Issuer's common stock acquired by the reporting person on May 15, 2026 pursuant to an employee stock purchase plan. |
| 2 | Common | Common Stock | 2026-08-05 | S | D | 5,849 | $29.00 | 67,828 | D | — | — | (F2) Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| 3 | Common | Common Stock | 2026-08-06 | M | A | 14,292 | $17.84 | 82,120 | D | — | — | |
| 4 | Common | Common Stock | 2026-08-06 | S | D | 5,000 | $29.00 | 77,120 | D | — | — | (F2) Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025. |
| 5 | Common | Common Stock | 2026-08-06 | S | D | 9,292 | $29.34 | 67,828 | D | — | — | (F2) Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025. |
| 6 | Derivative | Stock Option (Right to Buy) | 2026-08-05 | M | D | 5,849 | $0.00 | 74,715 | D | $17.84 · — to 2034-03-24 | 5,849 Common Stock | (F4) 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. |
| 7 | Derivative | Stock Option (Right to Buy) | 2026-08-06 | M | D | 14,292 | $0.00 | 60,423 | D | $17.84 · — to 2034-03-24 | 14,292 Common Stock | (F4) 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. |